BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21396935)

  • 1. Erythropoietin for oncology supportive care.
    McKinney M; Arcasoy MO
    Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human erythropoietin and interleukin-3 on erythropoietic recovery from acute anemia.
    Rosen BS; Levine EA; Egrie JC; Sehgal LR; Greenberg R; Rosen AL; Levine HD; Gould SA
    Exp Hematol; 1993 Oct; 21(11):1487-91. PubMed ID: 8405228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the clinical use and misuse of erythropoietin.
    Eagleton HJ; Littlewood TJ
    Curr Hematol Rep; 2003 Mar; 2(2):109-15. PubMed ID: 12901141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
    Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
    Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin: current status.
    Bunn HF
    Yale J Biol Med; 1990; 63(5):381-6. PubMed ID: 2293499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. FEDERATION OF THE FRENCH CANCER CENTRES (FNCLCC)].
    Spaëth D; Marchal C; Bataillard A; Blanc-Vincent MP
    Bull Cancer; 1999; 86(7-8):631-9. PubMed ID: 10477381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin-stimulating agents in oncology.
    Savona MR; Silver SM
    Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concern about the safety of erythropoietin in cancer patients].
    van der Lelie J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(16):920-2. PubMed ID: 18561786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.